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Continuous carboplatin infusion during 6 weeks' radiotherapy in locally
inoperable non-small-cell lung cancer: a phase I and pharmacokinetic
study
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Departments of'Pulmonary Diseases, 2Radiotherapy, 3Medical Oncology and4Pharmacy, University Hospital Groningen,
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Summary A phase I study was performed in 21 patients with previously untreated, locally inoperable,
non-small-cell lung cancer (NSCLC) with ambulatory continuous carboplatin infusion together with con-
tinuous thoracic irradiation over 6 weeks. A dose range for carboplatin of 15 mg m-2 day-' during the last 21
days (first level), during the last 31 days (second level), or during 6 weeks of the radiation period (third level)
and thereafter 20 or 25 mg m-2 day-' during 6 weeks of radiation (fourth and fifth level) was used. The total
radiation dose was 60 Gy given as 2 Gy day-i for 5 days week- . The first three patients received radiotherapy
without carboplatin. WHO grade III/IV leucopenia and thrombocytopenia occurred in the last two dose levels
in two out of six and one out of six patients with 20 mg m-2 day-' respectively, and in all three patients with
25 mg m2 day-' (dose-limiting toxicity). One local infection around the port and a subclavian vein throm-
bosis occurred. Radiation toxicity of the lung and oesophagus did not seem to be influenced by carboplatin
treatment. Out of 21 patients one had a complete response (CR), ten partial response (PR), six stable disease
(SD) and four progressive disease (PD). Total (TPt) and ultrafilterable plasma platinum (UPt) were measured
in the last three dose levels with atomic absorption spectrophotometry with Zeeman correction. The mean
(s.d.) level for TPt for 6 weeks at 15, 20 and 25mg m2 day-' was 0.76 (0.15), 0.78 (0.19) and 0.90 (0.22)
mg 1' for UPt 0.10 (0.03), 0.12 (0.02) and 0.20 (0.03) mg 1' respectively. TPt concentration levelled off after
3 weeks. The mean (s.d.) CLTB for UPt was 281 ± 21 ml min ' and correlated with glomerular filtration rate
(r = 0.61, P = 0.03). As estimated with the sigmoid E.. model defined by the Hill equation the percentage
reduction in platelets correlated with the area under the curve for UPt (r = 0.77). The maximum tolerable dose
of carboplatin with concomitant continuous 60Gy radiotherapy is 25 mg m2 day-'; the recommended dose
for phase II or III studies is 20mgm-2 day-' day for 6 weeks.
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The standard treatment for stage III non-small-cell lung
cancer (NSCLC) is local thoracic irradiation. In 1973 a
Radiation Therapy Oncology Group trial showed a
significant relationship between higher total dose of radiation
and control of tumour within the field as well as survival at 2
years (Perez et al., 1982). However, the high rate of distant
metastases and the still frequent failure within the irradiated
volume made the improvement in prognosis rather limited
(Perez et al., 1987). These failures provided a rationale for
the combination of radiation and chemotherapy.
For several years induction chemotherapy followed by
radiotherapy was used to reduce local and distant recurrences
and to improve survival. Some randomised trials showed
improved survival with this approach (Dillman et al., 1990;
LeChevalier et al., 1992), however others could not demon-
strate the value of induction chemotherapy (Cullen et al.,
1991; Mattson et al., 1991; Morton et al., 1991). A new
approach would be simultaneous administration of
chemotherapy and radiation therapy. In addition to a
cytoreduction by both treatments, a radiosensitising effect
might be of extra benefit. In vitro, radiosensitising effects
have been found for cisplatin and carboplatin (Douple, 1979;
Douple et al., 1985; Begg et al., 1987; Skov and MacPhail,
1991). Furthermore, platinum-containing regimens in ade-
quate doses have shown objective responses to clinical trials
with NSCLC (Bunn, 1989). In at least one out of four
randomised trials concurrent chemoradiation showed imp-
roved local control and doubling of the 2 year survival at the
cost ofconsiderable toxicity (Soresi et al., 1988; Ansari et al.,
1991; Trovo et al., 1991; Schaake-Koning et al., 1992). Car-
boplatin has reduced most of the toxicities of cisplatin treat-
ment, especially when it is administered as a continuous
infusion (Smit et al., 1991). In the present study the
feasibility and optimal dose of continuous carboplatin
infusion on an outpatient basis during local thoracic irradia-
tion in stage III NSCLC was analysed.
Patients and methods
Patients
Patients with histologically proven NSCLC were eligible if
they fulfilled the following criteria: age below 75 years,
locally unresectable NSCLC without supraclavicular nodes,
Eastern Cooperative Oncology Group (ECOG) performance
score < 2, serum creatinine < 120tmol
' or creatinine
clearance > 60 ml min-l, serum bilirubin < 2.0 mgdl-'
leucocytes > 3.0 x I0 1'- and platelets > 100 x I0 I-1.
Patients with prior chemo- or radiotherapy were ineligible.
Written informed consent was obtained from all patients.
The study was approved by the Medical Ethical Committee
of the University Hospital of Groningen.
Carboplatin
Carboplatin was supplied by Bristol Myers Squibb and dis-
solved in 5% glucose. Every 48 h patients were provided with
15 ml of freshly constituted solution in a 20ml syringe. A
portable battery-powered syringe driver (Graseby Medical
MS 16A) was connected to a venous access port (Infuse-A-
Port) with an extension tube and a Huber needle. The venous
access was attained by a standard subclavian vein puncture.
The subclavian line was a silicone rubber catheter, tunnelled
under local anaesthesia to a subcutaneously implanted metal
injection port (VAP) (Greidanus et al., 1987). Patients were
carefully instructed by an oncology nurse how to change
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syringes in the portable pump. The VAP was checked for
local infection every week; the needle and extension tube
were renewed in the third week of treatment.
Irradiation
Continuous thoracic irradiation delivered by a linear
accelerator with megavoltage photons (6 MV) was applied
for 5 days a week for 6 weeks. The total dose was 60 Gy in
30 fractions of 2 Gy. Simulation was performed in all
patients. The target volume encompassed all visible local and
regional disease with a 2 cm margin of normal tissue that is
based on examination of the CT scan of the thorax before
the start of the treatment. The target volume until 40 Gy
included also the mediastinum from 2 cm on above the sup-
rasternal notch to 5 cm below the carina and extended to
2 cm across the midline.
Until 40 Gy anterior-posterior opposed fields were both
treated at each treatment session. Thereafter, irradiation was
given to the original tumour site with a 2 cm margin using a
three-field technique or oblique fields to exclude the spinal
cord. No corrections for pulmonary field irradiation were
made. The dose compliance was within 5% of the planned
dose after recalculations from the daily dose records.
Study design
Three patients received radiotherapy only. Thereafter, the
first dose level of carboplatin was 15 mgm2 day-' given
during the last 21 days of the radiotherapy. The next level
was given during the last 31 days and the following level
during 6 weeks of radiotherapy. Further escalations in dose
were planned at 5 mg m2 day-' during 6 weeks of con-
tinuous irradiation.
Unacceptable toxicity was defined as non-haematological
toxicity (except alopecia) exceeding (but not including) WHO
grade II and/or haematological toxicity exceeding grade III.
Acute toxicity was defined as toxicity that appeared from the
start of treatment until 2 months after the end of the com-
bined treatment. At least three patients were enrolled in each
dose level. If unacceptable toxicity occurs in one out of three
patients then a total of six patients will be enrolled in that
level.
Patients were assessed with complete blood counts, liver
and renal function, weight, performance score and non-
haematological (WHO) toxicity score. Moreover, acute pul-
monary toxicity was scored with chest radiographs every 2
weeks, lung function tests with diffusion capacity
measurements (according to the recommendations by the
American Thoracic Society) including pulmonary membrane
function and capillary blood volume before, midway and 2
weeks after finishing treatment. A CT scan of the chest was
performed before and 3 weeks after the end of treatment.
Other non-haematological toxicity was scored independently
by two investigators using WHO criteria. The highest score
was used. Tumour response was measured according to
WHO criteria 3 weeks after the end of the combined treat-
ment (WHO, 1978).
Total (TPt) and ultrafilterable plasma platinum (UPt) were
measured with atomic absorption spectrophotometry with
Zeeman background correction. Samples were collected
weekly over 6 weeks of treatment in heparinised tubes (Veno-
ject; Omnilab, Breda, The Netherlands) on ice. For Tpt,
samples were centrifuged (1500 g for 5 min at ambient
temperature). An aliquot of 2 ml of plasma was then directly
ultracentrifuged (1800 g for 60 min at ambient temperature)
with an Amicon Centifree micropartition system with YHT
membranes (Amicon, Oosterhout, The Netherlands) to make
UPt samples. Samples were stored at - 20°C to await
analysis. The lower detection limit for TPt and UPt is
0.1 mg ml-' (s.d. 7.7%) and 0.025mg 1' (s.d. 5%) respec-
tively. Areas under the curve (AUC) for TPt and UPt were
calculated by the trapezoidal rule.
The pharmacodynamic linkage between the percentage
reduction in platelets and AUC to ultrafilterable platinum
has been modelled with the modified Hill equation (Egorin et
al., 1994):
E = (Ema.)(AUC)H/(AUC5o)H + (AUC)H
or
E = 100/1 + (AUC/AUC_O)-H)
where E represents the percentage decrease in platelets pro-
duced by AUC, which is the area under the concentration
curve for ultrafilterable platinum, Emax represents the maxi-
mum elicitable effect of 100% decrease in platelets and
AUC" represents the AUC associated with 50% ofEmu. H is
the Hill constant describing the sigmoidicity of the curve.
Results
Patients
Twenty-one patients were entered into this study. Their char-
acteristics are shown in Table I. Their median age is 60 years
(range 35-71) with a male-female ratio of 19:2. One patient
suffered a relapse after lobectomy 1 year before. In the other
patients no previous malignancies had been diagnosed.
Eleven patients gained weight during treatment, seven had a
stable weight and three lost weight. Performance score
(ECOG) improved in ten patients by 1 point and 11
remained stable. There was one CR (confirmed by surgical
resection), ten PRs, six SDs and four PDs.
Toxicity
Nineteen patients completed the treatment. In two patients at
the last dose level of 25mgm2 day-' carboplatin infusion
was stopped on days 31 and 28. The first patient developed
an infection at the VAP due to Staphyloccus aureus with
neutropenic fever. After removal of the VAP leucopenia and
temperature normalised within 5 days. In this patient
radiotherapy was postponed for 1 week. In the other patient
leucocytopenia grade IV and thrombocytopenia grade III led
to stopping of carboplatin, but not of irradiation. Another
complication of the VAP catheter was thrombosis of the
subclavian vein 3 weeks after the end of the treatment
(15mgm2 day' x 31 days). Because of these complica-
tions, in the last three patients we used a percutaneously
inserted venous catheter in the elbow with tip placement in
the superior vena cava (Gesco Per-Q-Cath, San Antonio, Tx,
USA). There were no complications.
Haemotological toxicity was dose limiting. Thrombo-
cytopenia developed at the highest dose level in the fifth and
sixth weeks of treatment, preceding leucocytopenia, which
was prominent 1 week after the end of treatment. Both
recovered within 2 weeks after completion of treatment. The
nadir of leucocytes and platelets is given in Table II. No
haematological toxicity was seen when carboplatin was given
Table I Patients' characteristics
n
Median age (years) (range)
Histology
Squamous
Adeno
Large cell
Performance score
0
2
Tumour stage
T3
T4
N2
N3
Median weight (kg) (range)
Weight loss > 10%
21
60 (35-71)
15
3
3
16
2
6
9
14
2
80 (55-105)
3
993
PACombined modalitytreatment instage Ill non-small.ceIl lungcancer
HJM Groen etal
994
for 21 or 31 days. A transient thrombocytopenia (grade I in
two out of nine patients in the two highest levels) was
noticed 5-7 weeks after finishing treatment in the last two
dose levels in all patients. No platelet transfusions were
necessary. Serum creatinine and creatinine clearance cal-
culated from the urine collected over 24h remained within
normal limits at all dose levels during and after treatment.
Non-haematological toxicity is described in Table III.
Oesophagitis was mild and most prominent in the fourth
week of treatment. It subsided in the second week after the
end of treatment, except in two patients whose complaints
disappeared in the third week. With a follow-up of 1 year no
late oesophagitis had been encountered. The mean length of
the oesophagus in the radiation field up to 40 Gy was 19 cm
and thereafter 14 cm with no differences between
oesophagitis WHO grades 0, 1 and 2. Acute radiation
damage was also mild: dry cough and slight radiographic
haziness in the radiation field from the fourth week on led to
WHO grade II toxicity in all patients. Clinical features of
pneumonitis such as fever did not develop. Corticosteroids
were not used. Spinal cord damage and alopecia did not
occur.
Lungfunction
Diffusion capacity corrected for alveolar volume (Kco)
measured in 12 patients (the last three dose levels) before
treatment was slightly decreased compared with age- and
gender-matched controls: 77% (26) of predicted (s.d.). There
was no change in Kco during and 2 weeks after treatment.
The pulmonary membrane factor (Dm) and capillary blood
volume (V,.p) were also reduced before treatment: 58% (18)
of predicted and 75% (32) of predicted respectively. Neither
of them changed significantly during or 2 weeks after treat-
ment. The total lung capacity before, during and after treat-
ment was 85% (15), 81% (12) and 87% (7) of predicted
(Table IV).
Pharmacokinetics
From the 15 mgm2day-' for 6 weeks carboplatin pharma-
cokinetics on three patients were analysed at each dose level.
Table II Haematological toxicity of 6 weeks' continuous
carboplatin infusion and concomitant radiation at the last three dose
levels
Carboplatin WBC x 1091' Platelets x 109 I' Days of continued
dose per day (nadir day) (nadir day) treatment
15mgm-2 2.2 (49) 253 (49) 42
3.7 (49) 176 (49) 42
5.0 (49) 101 (35) 42
20mgm-2 1.1 (45) 35 (44) 42
2.5 (45) 75 (40) 42
4.3 (36) 290 (36) 42
3.0 (56) 153 (36) 42
3.3 (42) 165 (42) 42
1.6 (44) 74 (37) 42
25 mgm-2 0.3 (38) 27 (34) 28
0.8 (49) 29 (37) 31
1.2 (44) 40 (37) 42
Table III Acute non-haematological toxicity in patients with
NSCLC treated with continuous infusion carboplatin and
radiotherapy (n = 21)
Toxicity WHO grade 0 I II III IV
Cough 7 14 0 0 0
Dyspnoea 15 5 1 0 0
Nausea 11 10 0 0 0
Vomiting 13 0 8 0 0
Oesophagitis 5 8 8 0 0
Pneumonitis 0 0 21 0 0
During carboplatin administration TPt levels increased
gradually without reaching steady state. The mean (s.d.)
plasma concentration of TPt for 6 weeks of treatment at 15,
20 and 25 mgm2day-' were 0.76 (0.15), 0.78 (0.19) and
0.90 (0.22) mg 1l respectively. UPt reached steady-state
levels within the first week with mean (s.d.) plasma concen-
trations during 6 weeks of treatment at 15, 20 and 25mg
m-2day-' of 0.10 (0.03), 0.12 (0.02) and 0.20 (0.03) mgl-'
respectively (Figure 1). The mean (s.d.) AUC for UPt (cal-
culated over the total period of 6 weeks) at 15, 20 and
25mgm-2 day-' was 4.6 (1.2), 5.6 (0.9) and 6.9 (1.5)g
min' 1-1. The mean (s.d.) total body clearance (CLTB) of
UPt was 281 (21) ml min'I and correlated with the creatinine
clearance measured in 24h urine (r=0.61, P=0.03). The
relationship between AUC for ultrafilterable platinum and
the percentage reduction in platelets was described by the
modified Hill equation as follows:
E=100/1 + (AUC/4.22)-295 (r= 0.77).
The values of the fitted parameters were: AUC50 (s.e.) = 4.22
(0.39) and Hill constant (s.e.) = 2.95 (0.91) (Figure 2). The
residuals showed no evidence of non-randomness.
Discussion
Traditionally, thoracic radiotherapy is the main treatment for
local inoperable NSCLC, despite the fact that its role is not
Table IV The lung function in NSCLC patients before, during and
after ambulatory infusional carboplatin and radiotherapy
Lung function Before During After
TLC 85 15 81 12 87+7
TLCO 69 21 67 21 75 24
K. 77±26 72±23 71 26
Dm 58 18 63 23 65 18
V<>,P 75±32 67±24 82±38
TLC, total lung capacity; TLCO, diffusion capacity; Kco, diffusion
capacity corrected for alveolar volume; Di, pulmonary membrane
factor; V,.p, pulmonary capillary blood volume. All measurements in
individual patients were in duplicate and the mean is expressed as
percentage of predicted ± s.d. (n = 12, from the last three dose
levels).
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Figure 1 The total (closed symbols) and ultrafilterable (open
symbols) plasma platinum levels during 6 weeks of continuous
carboplatin infusion combined with radiotherapy at carboplatin
doses of 15 (-), 20 (A), and 25 (V) mgm2 day-'. Each point
represents the mean ± s.e.m. of three patients. Measurement
points at weeks 5 and 6 at the dose level of 25mgm-2 day-'
have been omitted because of early discontinuation of carbop-
latin in two patients owing to toxicity. The lower straight line
represents the lower detection level of ultrafilterable platinum:
0.025mg 1'.100 -
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Figure 2 The relation betwec
ultrafilterable platinum using
the Hill equation. The dashed
(n = 12, r = 0.77).
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in almost one-third of the patients in the Schaake-Koning
. ,' study (1992) with daily cisplatin during radiotherapy, could
/* therefore be avoided. With a follow-up of 1 year no late
/ / - oesophagitis has yet been encountered. A short-lived throm-
,' * / - - bocytopenia and leucopenia in the last week of treatment and
a mild early oesophagitis were the most common problems.
Attention should be paid to the venous access port to prevent
/., infections and thrombosis of the subclavian vein. One option
is to remove the VAP at the end of the treatment; another
option is to use central venous catheters, which can be
changed any time.
Enhancement of radiation-induced lung dysfunction by
carboplatin was not observed in the first 3 months. The
,' progressive fibrotic reaction probably counteracted shrinking
of tumour tissue in the acute phase, keeping total lung
function (TLC) steady during and shortly after treatment.
Diffusion capacity remained unchanged. The initially
measured pulmonary membrane factor and to a lesser extent
4 6 8 10 the capillary volume were consistently low in comparison
rable platinum (g min- 1-') with matched controls, which might be interpreted as a more
extensive interstitial or small vessel involvement than could
thrombocytopenia and AUC for be expected from CT scan of the chest alone. However,
line istheg95o confidence interval during and after the combined treatment neither factors
changed. Animal studies with irradiation showed
inflammatory cells and protein leak in bronchoalveolar
lavage fluid and in histological sections of the lung from 2
weeks after radiation exposure (Travis, 1980; Rosiello, 1993).
Bonomi, 1986). It has been Interstitial and vascular changes could account for a persis-
to improve local control. Con- tent low pulmonary membrane factor and decreased pul-
be better than split course, and monary capillary volume (Collis and Steel, 1982; Collis,
ghtly better local control at the 1982). Toxicity measured by ventilation rate and lethality in
,ity (Salazar et al., 1976; Cox et mice showed that addition of platinum-containing drugs to
remain poor, mainly because of radiation gave no or hardly any acute damage (Von der
because local relapse rates at 1 Maase et al., 1986; Tanabe et al., 1987; Steel, 1988).
'erez et al., 1987). This was the One of the problems with continuous carboplatin infusion
otherapeutic agent that increases is that a progessively greater portion of UPt is accounted for
by radiosensitising and cytostatic by catabolic products of proteins to which platinum has been
icrometastases. Cisplatin has been covalently bound. The anisotropic, hydrophilic ultrafiltration
imits its use in clinical practice membrane has a narrow pore size distribution. Membrane
night be an alternative as it lacks pores have a diameter for molecules up to a molecular weight
rotoxicity. Higher total carbop- of about 30000. Therefore, measurements of UPt represent
with less toxicity by ambulatory not only free platinum but also platinum bound to different
e may compensate for the slower small proteins. This shows the limitation of the described
platin to its active form as com- method used for determination of platinum in the ultra-
or any schedule dependency of filtrate during continuous carboplatin infusion. However, the
idiation (Micetich et al., 1985; fact that there is a relationship between the decrease in
1989). In vitro studies with pro- platelets and AUC for ultrafilterable platinum (including pro-
atin suggest an increased number tein products) demonstrates that the ultrafiltrate contains an
ibits the same cytotoxic effects as active substance and is not just a non-specific measurement.
1985; Knox et al., 1986). Also, No data are available concerning the nature of the different
re with carboplatin does increase multiple protein species during prolonged carboplatin
For local control, radiosensitising infusion. The pharmacokinetics of continuous carboplatin
ncrease with longer exposure to infusion over 6 weeks demonstrated a low and constant UPt
be important, although this has level. The TPt concentration levels offafter about 3 weeks. In
(Douple et al., 1985; Skov and other studies with shorter periods of prolonged infusion TPt
reasons carboplatin was given does not reach steady state (Smit et al., 1991; Webster et al.,
:s of local irradiation. 1992). Assuming linear pharmacokinetics the mean total
,ith advanced cancers Smit et al. body clearance of UPt was about twice that of creatinine and
tolerable dose (MTD) for con- correlated with creatinine clearance. Possibly this high
atin of 30 mg m2 day-' over 21 clearance partly reflects the excretion of platinum bound to
oup of heavily pretreated patients small proteins. Carboplatin did not disturb renal function,
the MTD was 42 mg m2 day-' measured with endogenous creatinine clearances, but with
nfusion (Webster et at., 1992). In more sophisticated methods slight changes have been noticed
was dose limiting. We found a without clinical significance (Sleijfer et al., 1989). The Calvert
it chemoradiotherapy. A dose of formula describing the relation between carboplatin dose,
eks continuously, leading to a predicted AUC and glomerular filtration rate was not used.
m 2 carboplatin, could be given As in studies with carboplatin given by bolus injection there
ifusion on an outpatient basis. In is a positive correlation between the percentage decrease in
stage III NSCLC had good initial platelets and AUC for UPt. However, the decrease in
e not compromised by treatment. platelets predicted by the Egorin formula was not found,
Le optimal treatment scheme was indicating less toxicity for a given total dose with continuous
tudies substantial problems were infusion (Egorin et al., 1984). Reasons for this lack of cor-
niting and oesophagitis (Schaake- relation might be the concomitant radiotherapy and the fact
et al., 1992; Reboul et al., 1992). that the Egorin formula was based on the pharmacokinetics
testinal toxicity, such as occurred of a single bolus dose. Although previous studies comparing
0
I
I
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the pharmacokinetics and thrombocytopenia associated with
carboplatin found a linear relationship, subsequent analyses
over wider ranges of carboplatin AUC have shown that this
relationship is better described by a sigmoid Em.,, model
defined by the Hill equation. This model was also applicable
on the percentage decrease of platelets and AUC for
ultrafilterable platinum during continuous infusion with
carboplatin.
Local tumour control is determined by tumour size, radia-
tion dose, tumour resistance factors, performance score and
to a lesser extent the intrapulmonary localisation. Tumour
size is important because sterilisation of tumour cells is only
possible in small tumours (Dosoretz et al., 1993). Also
chemotherapy achieves better results in smaller tumours. For
radiobiological reasons split-course radiation incorporated
into combination treatment is inferior to continuous radia-
tion probably owing to repopulation or regeneration with
resistant tumour cells during the split period. The effects of
irradiation on local tumour control are difficult to assess
because of an extensive fibrotic reaction around the shrinking
tumour. Response rates of about 50% have been reported
(Perez et al., 1982; Dosoretz et al., 1993). The response rate
to carboplatin alone of NSCLC patients is low at around
10% (Kreisman et al., 1987; Bunn, 1992). In a phase I study
with continuous carboplatin infusions alone 5/17 evaluable
patients with advanced malignancies responded (Smit et al.,
1991). However, pure local radiation treatment hardly
influenced survival (Perez et al., 1982), while systemic treat-
ment with platinum drugs offers slightly improved survival
(Dillman et al., 1990; Schaake-Koning et al., 1992).
In conclusion, the optimal dose for continuous carboplatin
infusion over 6 weeks is 20mgm-2day-' in combination
with locoregional fractionated radiation therapy of 30 frac-
tions of 2 Gy. Toxicity has been remarkably mild. A phase
III study is necessary to evaluate survival benefit and clinical
impact on local control and quality of life for a large group
of inoperable stage III NSCLC patients.
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